Johnson & Johnson (JNJ) Stock Analysis

NYSE$278.81-1.33%AI analysis

Johnson & Johnson is a diversified healthcare conglomerate operating in pharmaceutical innovation and medical device manufacturing across two main segments: Innovative Medicine (oncology, immunology, neuroscience) and MedTech (surgical, orthopedic, and vision products). Investors research JNJ as a large-cap healthcare holding with a long dividend history and exposure to both high-margin pharmaceuticals and medical devices.

Get a full AI research report on JNJ

6-step deep analysis in ~90 seconds. Quick research is free — no signup.

Analyze free →

What does Johnson & Johnson do?

Johnson & Johnson generates revenue through two primary channels: Innovative Medicine, which develops and sells prescription pharmaceuticals for oncology, immunology, and other therapeutic areas through healthcare professionals and distributors; and MedTech, which manufactures surgical instruments, orthopedic implants, cardiovascular devices, and vision products sold to hospitals, physicians, and clinics globally. The company operates a vertically integrated model spanning research, manufacturing, and distribution, with products reaching end-users through both professional healthcare settings and retail channels. Gross margins of 67.8% reflect the high-value nature of pharmaceutical and medical device products, while operating margins of 26.6% demonstrate significant operational leverage.

Bull case

  • ✓Strong dividend yield of 1.88% with a payout ratio of 80%, indicating a mature, cash-generative business that has historically returned capital to shareholders.
  • ✓Diversified revenue streams across two distinct segments (Innovative Medicine and MedTech) reduce dependence on any single therapeutic area or product category.
  • ✓Gross margin of 67.8% and operating margin of 26.6% demonstrate pricing power and operational efficiency typical of established pharmaceutical and medical device leaders.
  • ✓Return on equity of 20% indicates effective use of shareholder capital relative to peers in the healthcare sector.
  • ✓Forward P/E of 24.5x is materially lower than trailing P/E of 43.2x, suggesting market expectations for earnings growth or normalization.

Bear case

  • ✗Trailing P/E of 43.2x is elevated relative to historical averages for large-cap healthcare, raising questions about current valuation relative to near-term earnings.
  • ✗PEG ratio of 3.22 indicates the stock may be priced at a premium relative to expected earnings growth rates, depending on growth assumptions.
  • ✗Quick ratio of 0.653 is notably below 1.0, suggesting potential liquidity constraints if the company faced near-term obligations without relying on inventory conversion.
  • ✗Debt-to-equity ratio of 54.8% reflects substantial leverage, which may limit financial flexibility during downturns or for strategic acquisitions.
  • ✗High payout ratio of 80% leaves limited room for dividend growth without corresponding earnings increases, constraining capital allocation flexibility.

JNJ valuation & financial health

Johnson & Johnson trades at a trailing P/E of 43.2x with a forward P/E of 24.5x, indicating the market is pricing in meaningful earnings expansion ahead. The company's price-to-book ratio of 8.4x and EV/EBITDA of 20.7x reflect premium valuation typical of established healthcare leaders with stable cash flows. Financial health shows mixed signals: the current ratio of 1.016 suggests adequate short-term liquidity, but the quick ratio of 0.653 indicates reliance on inventory turnover. Return on assets of 8.46% and return on equity of 20% demonstrate profitable capital deployment, though the 54.8% debt-to-equity ratio indicates meaningful leverage. The 80% payout ratio leaves limited room for dividend expansion without earnings growth.

The bottom line

Johnson & Johnson presents a classic large-cap healthcare profile: a diversified, cash-generative business with strong margins and a long dividend history, but trading at valuations that reflect high growth expectations relative to historical norms. Key considerations include whether the forward P/E of 24.5x fairly values expected earnings growth, whether leverage at 54.8% debt-to-equity constrains strategic flexibility, and whether the 80% payout ratio is sustainable if growth slows. Factors to monitor include pipeline progress in Innovative Medicine, competitive pressures in MedTech, patent expirations, and macroeconomic sensitivity of healthcare spending.

Frequently asked questions

What does Johnson & Johnson do?

Johnson & Johnson operates two main business segments: Innovative Medicine, which develops and sells prescription pharmaceuticals for oncology, immunology, neuroscience, and other therapeutic areas; and MedTech, which manufactures surgical instruments, orthopedic implants, cardiovascular devices, and vision products sold to hospitals and healthcare professionals globally.

Is JNJ overvalued at current prices?

Johnson & Johnson's trailing P/E of 43.2x is elevated relative to historical averages, though the forward P/E of 24.5x suggests the market expects earnings growth to narrow that gap. Whether current valuation is justified depends on your view of future earnings growth, pipeline strength, and acceptable risk-adjusted returns for a mature healthcare company.

How financially healthy is Johnson & Johnson?

The company demonstrates strong profitability with a 20% return on equity and 26.6% operating margins, but carries substantial debt at 54.8% debt-to-equity and has a quick ratio of 0.653, indicating some reliance on inventory conversion for liquidity. Overall financial health is solid for a mature company, though leverage constrains flexibility.

Does Johnson & Johnson pay a dividend?

Yes, Johnson & Johnson pays a dividend with a yield of 1.88% and a payout ratio of 80%, indicating a mature company returning most earnings to shareholders. The high payout ratio leaves limited room for dividend growth without corresponding earnings increases.

What are the main risks to Johnson & Johnson stock?

Key risks include patent expirations on major drugs, competitive pressure in medical devices, regulatory changes affecting drug pricing, litigation exposure, and macroeconomic sensitivity of healthcare spending. Additionally, the elevated valuation and high leverage reduce margin for error.

How does JNJ compare to other healthcare stocks?

Johnson & Johnson is larger and more diversified than many pure-play pharmaceutical or device companies, offering exposure to both segments. Its dividend yield of 1.88% and payout ratio of 80% are typical of mature healthcare leaders, though valuation multiples vary significantly across the sector depending on growth profiles and pipeline strength.

Research JNJ with AI in seconds

Company profile, financials, events, competition, risks and synthesis — automated.

Start free — no signup

For informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.